Kidney Preclinical research
Kidney Preclinical research

Dr. Nourdine FARESSE

Founder, C.E.O

Our vision

At NEPHRIX Biosolutions, we are driven by a vision to transform kidney disease research through innovative, high-quality, and ethically-driven preclinical solutions. Founded by Dr. Nourdine Faresse, a distinguished leader in nephrology research, the company embodies his dedication to advancing the understanding and treatment of chronic kidney diseases (CKD).

With extensive expertise spanning academia and industry, Dr. Faresse has pioneered specialized preclinical models that enhance the predictability of clinical outcomes in kidney disease research. His leadership and groundbreaking work have positioned NEPHRIX Biosolutions as a trusted partner for pharmaceutical, biotech, and academic innovators seeking to develop life-changing therapies.

We are committed to addressing the global burden of kidney disease by bridging the gap between discovery and clinical success, reducing late-stage drug development risks, and improving patient outcomes. Together, we are shaping the future of nephrology research, one breakthrough at a time.

Advisory Board

Andrew HALL
Nephrologist
Professor at University of Zurich
Abdelkrim GHERRABTI
C.E.O Naturamole
Expert in Biotechnology industrialization
Jean-Michel LAGARDE
C.E.O Imactiv-3D
Expert in microscopy imaging